FDA Approves Revolution Pancreatic Cancer Drug
The US Food and Drug Administration has approved Revolution Medicines daily pill Rasonque for advanced pancreatic cancer. The targeted treatment significantly improves patient survival rates and quality of life compared to traditional chemotherapy.
Xurve View
Insights:
Xurve View
REVOLUTION MEDICINES INC secured FDA approval for its pancreatic cancer drug Rasonque after clinical trials showed it doubled patient survival rates. The once-daily pill targets advanced cases, offering a new treatment path for the deadly disease. The rollout follows a surge in investor interest and early access programs across the United States.
